Cryptococcal meningoencephalitis in an IgG(2)-deficient patient with multiple sclerosis on fingolimod therapy for more than five years – case report

BACKGROUND: Fingolimod (Gilenya®), a first-in-class sphingosine-1-phosphate receptor modulator is approved for the treatment of relapsing-remitting multiple sclerosis. Fingolimod-induced selective immunosuppression leads to an increased risk of opportunistic infections such as cryptococcosis. So far...

Descripción completa

Detalles Bibliográficos
Autores principales: Wienemann, Tobias, Müller, Ann-Kristin, MacKenzie, Colin, Bielor, Carina, Weyers, Vivien, Aktas, Orhan, Hartung, Hans-Peter, Kremer, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187502/
https://www.ncbi.nlm.nih.gov/pubmed/32340606
http://dx.doi.org/10.1186/s12883-020-01741-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187502/
https://www.ncbi.nlm.nih.gov/pubmed/32340606
http://dx.doi.org/10.1186/s12883-020-01741-0

Ejemplares similares